Brief: Neurocrine Biosciences Reports Positive Phase 2 Data For NBI-1117568 In Adults With Schizophrenia
28/08/2024 12:49
Aug 28 (Reuters) - Neurocrine Biosciences Inc NBIX.O :
* NEUROCRINE BIOSCIENCES REPORTS POSITIVE PHASE 2 DATA FOR
NBI-1117568 IN ADULTS WITH SCHIZOPHRENIA
* NEUROCRINE BIOSCIENCES INC -NBI-'568 WAS GENERALLY SAFE
AND WELL
TOLERATED AT ALL DOSES STUDIED
* NEUROCRINE BIOSCIENCES INC -ONCE-DAILY 20 MG DOSE MET
PRIMARY
ENDPOINT
Source text for Eikon: ID:nPn14t6kVa
Further company coverage: NBIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurocrine Biosciences
See all newsBrief: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall